Measurment of disinfection processes

Disinfection procedures made easy

Disinfection testing

Measurement of disinfection potential

NeoVirtech labs

We only score infectious viruses…

Our technology allows us to quickly calibrate and validate the development of disinfection devices. We can study all types of disinfection processes on our viruses and calculate the precise abatement to determine the optimal conditions of use.

We have already participated in the development of chemical, physical or radiative disinfection processes leading to the commercialization of innovative materials and decontamination devices. Contact us for more information.

Partnership with VirHealth for your normative tests

VirHealth SAS is a French biotechnology company focusing its activity on the measurement of virucidal/antiviral activities of products, devices, and technologies for disinfection using standardized and bespoke experimental approaches in an ISO9001 environment. The company provides services to investigate virucidal activity of disinfectant products and  equipment according to FR/EN/ASTM standards and has a strong expertise in the evaluation  of the antiviral activity of surface, materials, and textiles. Moreover, VirHealth develops bespoke decontamination procedures for analyzing of equipment and technologies (radiation, chemical, physical) according to specific customer needs

Olivier Authier
The goal of CLINIT Technologies was to design and manufacture an efficient UV disinfection box but on our market, all is invisible : viruses and UV-C radiation. So how to prove the efficiency on viruses, how to show it to our customers ?We contacted NEOVIRTECH seeking for answers, with the aim to guarantee the effect of our e-Box and attest it by a report. We found more than scientists. We found involved people with high reactivity, high availability, highly skilled sharing same values as us. Their auto fluorescent technology is magic, in real time we can see virus destruction. Amazing !!! In an agile way of working, and thanks to fast results, we reached our objectives in a very short time. By adjusting our box to the good level of radiations, we guarantee high efficiency and cherry on the cake : illustrated by beautiful images of virus eradication in real time. NEOVIRTECH is more than an independent laboratory, it’s a center of excellence in their domain and a source of improvement for us
Olivier Authier
Clinit Technologies
Thursday, August 31, 2017
Dr. Philippe Erbs
Transgene SA is a biopharmaceutical company developing for more than 30 years innovative targeted-immunotherapies to answer unmet medical needs in the oncology and infectious disease fields. We were looking for a rapid and efficient solution to investigate the behavior of our products using high-resolution quantitative microscopy. NeoVirTech’s autofluorescence technology and screening platform allowed us to precisely visualize, understand and compare the behavior of our products directly using live cell microscopy techniques. The beauty and quality of the data they can generate open a new perspective for our activities, boosting up our research and validation processes. Thank you NeoVirTech for this ongoing precious collaboration.
Dr. Philippe Erbs
Oncolytic Virus Department. Transgene S.A, Illkirch Graffenstaden, France
Thursday, August 31, 2017

Drug discovery

Evaluating drug’s performance, finding tomorrows blockbusters

Drug discovery

We can adapt the ANCHOR™ system to any kind of DNA, whether it is viral, animal or plant cell-based

It is possible for us to carry out drug discovery campaigns in various fields (gene therapy, oncology, etc.) using the Anchor system.

We can also offer to label a  protein target of your choice and watch the modulation of its expression by immunofluorescence in the presence of different inhibitors or activators of interest. Our screening platform equipment (CellInsight CX7) will allow us to perform many conditions in a short time and with sensitivity and quantification at the cellular level. We have a strong track record of screening campaign leading to drug discovery and patent protection.

Antiviral

Virus replication NeoVirtech

Our ANCHOR™ viruses are available in high-throughput imaging, making it a major tool for antiviral research and development. Combined with HCS microscopy and detection algorithm, it provides the fastest and the most robust techniques to discover new antivirals.

This allows us to rapidly set up the entire pre-clinical antiviral development pipeline:

  • drug discovery campaign (low, medium or high number of compounds), selectivity index calculation, hit sorting
  • hit validation and lead development
  • Determination of broad spectrum activities
  • Mechanism of Action
  • Target identification, resistant strain generation
Dr Daniel Gillet
We are developing inhibitors of intracellular trafficking pathways that block virus entry into cells. NeoVirTech’s technology allows for precise ranking of sets of analogues according to their antiviral potencies and selectivity indexes. Working with NeoVirTech was a great experience. Preparatory discussions were rich and efficient, adaptation of protocols to our needs was very successful, antiviral screening of our molecules was done rapidly, and activity reports were clear and informative. The team was always available to answer our questions. We warmly recommend NeoVirTech for the screening and potency assessment of antiviral molecules on designated viruses.
Dr Daniel Gillet
Frédéric Joliot Institute for Life Sciences, CEA Paris Saclay
Thursday, August 31, 2017
Enrique Tabares, CEO of MicroA A.S., Norway
Neovirtech have carried out several anti-viral studies for MicroA, on a range of targets. Both before and after the studies, we were impressed with their quick responses to our queries, very thorough technical approach and their support in data interpretation. Many thanks to the Neovirtech team for their hard work!
Enrique Tabares
CEO of MicroA A.S., Norway
Thursday, August 31, 2017

Oncology

Virus as a cancer therapy

Oncology

Oncolytics vectors

Conventional cancer treatments have limited effectiveness in many cases. Oncolytic therapy, based on the use of armed viruses directed against tumor cells, offers new perspectives in the fight against this global scourge.

In this context, our ANCHOR™ system allows the visualization of the early stages of infection down to the single cell level and the rapid quantification of viral replication. This real-time monitoring will accelerate the understanding and development of this new anti-cancer therapy and identify activator or inhibitor of your oncolytic product.

Construction of autofluorescent oncolytic vectors

Our experience in virus modification and the speed of implementation of our system can be a real asset to your product development. The real-time visualization of the virus particles allows a rapid response to many of the problems encountered in the development of oncolytic viruses. The ANCHOR technology allows the assessment of oncolytic potential without fixation, extraction or staining.

Cell line efficiency and in vivo testing

One of the main limitations of oncolytic therapies remains the permeability of cells to viruses. Many factors influence permissiveness, such as the cell type or the target organ. Also, information about the infection capacities and replication level depending on cell types can be difficult to assess. We can test a specific oncolytic product on different cell lines and test for their infection and replication capacity according to cell origin, multiplicity of infection or presence of a compound of interest. We can also propose to test the activity of oncolytic viruses on specific mouse models.

Drug discovery, oncolytic modulators

Using autofluorescent oncolytic viruses, we can measure the impact of the presence of a molecule of interest on virus infection and replication capacities. Molecules can be from different origin such as small molecules, antibodies, siRNA. This offer will help you discover the mechanistic and biological pathways behind oncolytic activities. The oncolytic activity can be modulated by activating the oncolytic potential on specific cell lines or inhibiting targeted replication.

Interaction with pre-existing treatments

The use of anti-cancer therapies is often performed in combinations for a better anti-tumor effect. We can study for you the impact of classical anti-cancer drugs combined with your oncolytic virus. The objective is to increase efficacy by detecting synergistic combination and avoid antagonism by preventing association of molecules that will impair viral infection or replication.

Pr. Pierre Cordelier
We are fortunate to collaborate with NeoVirtech on several projects. They provide unique strategies to better address complex biological questions in live cells in real-time. With their help, we were able to visualize for the first time the behavior of oncolytic virus in preclinical models of pancreatic cancer, a disease with no cure. We obtained crystal clear experimental data that could definitely accelerate the transfer of therapeutic innovation to patient with this disease. I highly recommend Franck and team, as seeing is believing !
Pr. Pierre Cordelier
CRCT Inserm
Thursday, August 31, 2017
Dr. Philippe Erbs
Transgene SA is a biopharmaceutical company developing for more than 30 years innovative targeted-immunotherapies to answer unmet medical needs in the oncology and infectious disease fields. We were looking for a rapid and efficient solution to investigate the behavior of our products using high-resolution quantitative microscopy. NeoVirTech’s autofluorescence technology and screening platform allowed us to precisely visualize, understand and compare the behavior of our products directly using live cell microscopy techniques. The beauty and quality of the data they can generate open a new perspective for our activities, boosting up our research and validation processes. Thank you NeoVirTech for this ongoing precious collaboration.
Dr. Philippe Erbs
Oncolytic Virus Department. Transgene S.A, Illkirch Graffenstaden, France
Thursday, August 31, 2017

Virus collection

The most extended virus collection with a One Health vision

Virus collection

For human and animal, antiviral screening

We can manage the construction of any kind of autofluorescent viruses or viral vectors for imaging application. We work on different kind of starting materials, from plasmid to large oncolytic vectors. Our technology has been applied to investigate the dynamics of a broad variety of DNA. Our virus collection is constantly expending.

As the ANCHOR system is not suitable to tag RNA viruses, we use classical virology readouts such as high throughput quantification of cytopathic effect, TCID50 or qPCR. Other readouts such as high throughput immunofluorescence are also available for some viruses.

ANCHOR™ tagged viruses

Any viruses having a dsDNA phase can be tagged with ANCHOR™. Here you will find a list of viruses available for immediate use. We annually expand this collection with new viruses to quickly respond to human or veterinary threat.

Your virus of interest is not in this list? Do not hesitate to contact us, we will find a solution!

Note: Viruses having biodefense applications are underlined. Italic implies availability of in vivo efficacy testing

Human market

Herpes virus
Retrovirus
  • Lentivirus HIV1 derived ANCHOR (several including IN deficient, in collaboration with GEG Tech)
  • HIV1 ANCH (in collaboration with  Pasteur Institute)
  • HPV16 ANCH (in collaboration with Munster university)
Adenovirus
Hepadnavirus
  • HBV ANCH (in collaboration with Gotteborg institute)
Other viruses
  • AAV2/H1 ANCH

Animal market

Poxvirus
  • MYXV Vaccinal strain ANCHOR
  • MYXV pathogenous strain ANCHOR
  • AFSV ANCHOR (in collaboration with Madrid University)
  • Cowpox ANCHOR
  • LSDV ANCHOR (in recombination)
Herpes virus
  • Equine Herpes Virus 1 ANCHOR
Baculovirus
  • AcMNPV ANCHOR

Non-ANCHOR™ tagged viruses

We work on other non-ANCHOR tagged viruses on request.

Note: Viruses having biodefense applications are underlined. Italic implies availability of in vivo efficacy testing

Human market

RNA viruses

Animal market

RNA viruses
  • Feline Calicivirus,
  • Avian influenza (including highly pathogenous H5N8)
DNA viruses
  • EHV4

Virology

Fluorescent virus for antiviral discovery & measurement of disinfection processes

Virology

Construction of autofluorescent vector and viruses for human and animal

NeoVirTech has developed a breakthrough technology to directly visualize and quantify in real time virus/viral vector infection and replication in living cells: the ANCHOR™ technology.

Several studies can be developed such as antiviral testing, inactivation solution testing or the development of decontamination devices (UV, ozone…) on different supports: cell lines, live human skin explants, surfaces (stainless steel, tissues, masks…) or even with materials that have a direct biocidal activity. We can test also your own material on request (fabric, leather, etc…).

We are constantly innovating to find the most appropriate solution to provide our customer state of the art virology testing.

Technology NeoVirtech

ANCHOR™ tagged viruses

Any viruses having a dsDNA phase can be tagged with ANCHOR™. Here you will find a list of viruses available for immediate use. We annually expand this collection with new viruses to quickly respond to human or veterinary threat.

Your virus of interest is not in this list? Do not hesitate to contact us, we will find a solution!

teamneo095bis

Non-ANCHOR™ tagged viruses

We work on other non-ANCHOR tagged viruses on request.

As the ANCHOR system is not suitable to tag RNA viruses, we use classical virology readouts such as high throughput quantification of cytopathic effect, TCID50 or qPCR. Other readouts such as high throughput immunofluorescence are also available for some viruses.

Pr. Claude Gros
Chemistry of porphyrins and corroles is at the heart of our research activities. With more than 25 years of expertise in macrocyclic chemistry (www.icmub.fr), we had several hundred porphyrin and corrole derivatives in our laboratory, mainly dyes or molecular probes developed for health applications that we were looking to develop. We were interested in testing the activity of these compounds in the anti-infectious domain. NeoVirTech was immediately responsive for this project, and with high professionalism, completely met our needs. Their expertise in screening and the speed and quality of the generated data led us to rapidly identify 3 hit compounds in our library as new inhibitors of hCMV as well as pox-viruses. These results were recently published in ACS Infectious Diseases (2 articles) and RSC Med Chem (2 back-to-back articles). 2 patents were also co-filed. Without the help and the strong expertise of NeoVirTech, it would not have been possible to rapidly test and value our library and valorize our work so quickly! It opens new perspectives to our research activities. Many thanks to NeoVirTech for this very efficient and precious collaboration!
Pr. Claude Gros
Institut de Chimie Moléculaire de l'Université de Bourgogne
Thursday, August 31, 2017
Dr. Philippe Erbs
Transgene SA is a biopharmaceutical company developing for more than 30 years innovative targeted-immunotherapies to answer unmet medical needs in the oncology and infectious disease fields. We were looking for a rapid and efficient solution to investigate the behavior of our products using high-resolution quantitative microscopy. NeoVirTech’s autofluorescence technology and screening platform allowed us to precisely visualize, understand and compare the behavior of our products directly using live cell microscopy techniques. The beauty and quality of the data they can generate open a new perspective for our activities, boosting up our research and validation processes. Thank you NeoVirTech for this ongoing precious collaboration.
Dr. Philippe Erbs
Oncolytic Virus Department. Transgene S.A, Illkirch Graffenstaden, France
Thursday, August 31, 2017